Figure 5.
Figure 5. Neutralizing activities of monoclonal and polyclonal IgGs or their corresponding Fab or F(ab′)2 fragments when iMDDCs or PHA-stimulated PBMCs were used as HIV-target cells. The percentages of infected iMDDCs or PBMCs were determined by flow cytometry in the presence of increasing concentrations of purified polyclonal IgG (A-B) or neutralizing mAb 447-52D (C) and their corresponding Fab or F(ab′)2 fragments. Competition experiments were performed by addition of recombinant gp160 (at 30 μg/mL; ▦) or cyclized V3 loop peptide (at 70 μg/mL; ▧) to mAb 447-52D and purified HIV-1BaL for 1 hour before addition of iMDDCs (D). Values are mean ± SD of 3 independent wells from one representative experiment.

Neutralizing activities of monoclonal and polyclonal IgGs or their corresponding Fab or F(ab′)2 fragments when iMDDCs or PHA-stimulated PBMCs were used as HIV-target cells. The percentages of infected iMDDCs or PBMCs were determined by flow cytometry in the presence of increasing concentrations of purified polyclonal IgG (A-B) or neutralizing mAb 447-52D (C) and their corresponding Fab or F(ab′)2 fragments. Competition experiments were performed by addition of recombinant gp160 (at 30 μg/mL; ▦) or cyclized V3 loop peptide (at 70 μg/mL; ▧) to mAb 447-52D and purified HIV-1BaL for 1 hour before addition of iMDDCs (D). Values are mean ± SD of 3 independent wells from one representative experiment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal